Name: 글로벌 시장 동향
SKU: PH1623
Availability: InStock

보고서 요약(국문)

개요
전 세계 폐경기 안면홍조 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
폐경기 안면홍조는 50~55세 여성에게서 폐경기에 나타나는 가장 흔한 증상입니다. 이는 호르몬, 특히 에스트로겐의 변동으로 인해 발생하며, 심계항진과 어지럼증이 동반될 수 있습니다. 호르몬 주사제는 안면홍조 치료에 주로 사용되며, 많은 여성들이 선호하는 치료법입니다.
존스 홉킨스 의과대학(2023)에 따르면, 모든 여성의 약 75%가 갑작스럽고 짧으며 주기적인 체온 상승을 경험합니다. 일반적으로 안면홍조는 마지막 생리 전에 시작되며, 여성의 80%는 2년 이내로 지속됩니다. 치료에는 호르몬 요법, 항우울제 등이 포함됩니다. 그러나 에스트로겐 요법은 폐경기 안면홍조 완화에 가장 효과적인 치료법입니다.
시장 동향: 동인 및 제약 요인
폐경기 여성 증가
폐경기는 모든 여성이 일생에 한 번쯤 겪어야 하는 가장 흔한 현상 중 하나입니다. 증상은 개인마다 다르며, 안면홍조, 야간 발한, 성교 시 통증, 기분 변화 등이 나타날 수 있습니다. 대부분의 여성은 50~55세에 폐경기를 맞이합니다. 미국 인구 조사 자료에 따르면 45~60세 여성 중 1,500만 명 이상이 직장에 다니고 있습니다. 제공된 자료에 따르면 전 세계적으로 폐경기 여성의 수가 증가하고 있습니다.
미국에서 폐경기는 평균 51.3세에 발생합니다. 미국 국립보건원(NIH)은 2023년에 전 세계 여성의 약 80%가 다양한 심각도의 혈관운동성 증상(VMS)을 겪고 있으며, 이는 삶의 질과 전반적인 건강에 영향을 미칠 수 있다고 밝혔습니다.

메이요 클리닉(2022)에 따르면, 2030년까지 전 세계 폐경기 및 폐경 후 여성 인구는 12억 명으로 증가할 것으로 예상되며, 매년 4,700만 명의 새로운 폐경기 여성이 추가될 전망입니다.
또한, 폐경기 관리 관련 여성 지출 증가, 여성들의 인식 제고, 신약 개발의 발전 등이 향후 시장 성장을 견인할 요인으로 예상됩니다.
호르몬 약물의 부작용
호르몬 요법의 부작용으로는 장기간 사용 시 자궁내막암 위험 증가, 혈전 및 뇌졸중 위험 증가 등이 있습니다. 조기 폐경으로 인해 호르몬 요법을 일찍 시작한 여성의 경우 치매 발생 위험이 높아질 수 있습니다. 또한, 장기간 약물 복용 시 담석 및 담석 관련 질환이 흔하게 발생할 수 있습니다.
시장 세분화
전 세계 폐경기 안면홍조 치료제 시장은 치료 방법, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

호르몬 치료 부문은 시장 점유율의 약 43.1%를 차지했습니다.
호르몬 치료는 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 예를 들어, 에스트로겐과 같은 호르몬 불균형은 갱년기 증상의 주요 원인입니다. 호르몬 수치가 감소하면 안면 홍조, 야간 발한과 같은 극심한 증상이 나타납니다. 몇몇 헬스케어 스타트업은 많은 여성의 안면 홍조를 완화하기 위해 호르몬 보충제를 출시했습니다.

예를 들어, 2023년 8월 스타트업인 리밸런스 헬스(Rebalance Health)는 안면 홍조, 야간 발한 등의 증상을 겪는 폐경기 여성의 호르몬 균형을 되찾는 데 도움을 주는 트로키를 출시했습니다.
또한, 2022년 5월 홀로그램 사이언스(Hologram Sciences)는 안면 홍조, 야간 발한, 기분 변화 등 폐경기 증상을 완화하는 데 도움이 되는 엄선된 영양 보충제를 선보이는 뷰티 및 웰니스 브랜드인 페놀로지(Phenology)를 출시했습니다.
2023년 4월에는 pH-D 페미닌 헬스(pH-D Feminine Health)가 여성의 폐경기 건강을 지원하는 새로운 경구 보충제 라인을 출시했습니다.
지역별 분석
북미는 2022년 시장 점유율의 약 40.2%를 차지했습니다.
미국에서 폐경기 증상을 경험하는 여성의 수가 적극적으로 증가함에 따라 북미는 앞으로도 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 예를 들어, 쿠유나 지역 의료 기관(Cuyuna Regional Medical Organisation)에 따르면 2022년 미국에는 50세 이상 폐경기 여성 6,400만 명이 있습니다.
미국에서 45세 이상 직장 여성의 수가 증가함에 따라 폐경기 관련 의료 비용도 증가하고 있습니다. 예를 들어, 뉴욕 타임스(The New York Times)는 2023년 폐경기로 인해 미국 여성들이 연간 약 18억 달러의 근로 시간 손실을 입는다고 추정했습니다.
북미 폐경 학회(North American Menopause Society)는 2023년 2025년까지 전 세계 폐경기 여성의 수가 11억 명으로 증가할 것으로 예상했습니다.
코로나19 영향 분석
코로나19는 폐경기 안면홍조 시장에 중간 정도 또는 그 이하의 영향을 미쳤습니다. 코로나19 확진자 증가로 인해 코로나19 치료제 및 백신 개발에 대한 관심이 집중되었습니다. 봉쇄 조치 시행으로 공급망이 차질을 빚었고, 이것이 이 시장에 가장 큰 영향을 미쳤습니다. 폐경기 안면홍조는 치료가 불가능하고 관리만 가능한 질환이기 때문에, 감염 확산 우려로 병원 방문을 꺼리는 사람들이 많아 가정 요법이 고려되기도 했습니다.
경쟁 환경
폐경기 안면홍조 시장의 주요 글로벌 기업으로는 Pfizer Inc., AbbVie Inc., Bayer, Amneal Pharmaceuticals LLC, Serum Institute of India Pvt. Ltd., Cipla Limited, Camber Pharmaceuticals, Inc., Merck KGaA, Algen Healthcare Ltd, Biosynth 등이 있습니다.
주요 개발 사항
• 2023년 5월, Astellas Pharma US, Inc.에서 개발한 Veozah(페졸리네탄트)가 폐경기로 인한 중등도에서 중증의 혈관운동성 증상, 즉 안면홍조 치료제로 미국 식품의약국(FDA)의 승인을 받았습니다.

• 2023년 10월, Elda Health는 사업 영역 확장을 위해 엄선된 제품 포트폴리오를 출시했습니다. 인도에 본사를 둔 Elda Health는 폐경기로 고통받는 인도 여성들에게 도움을 주는 것을 목표로 합니다.
보고서 구매 이유

• 치료법, 투여 경로, 유통 채널 및 지역별 글로벌 폐경기 안면홍조 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 폐경기 안면홍조 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 폐경기 안면홍조 시장 보고서는 약 61개의 표, 57개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Menopausal Hot Flashes Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Menopausal hot flashes are the most common symptoms observed in 50-55 years women during menopause. It is caused by hormone fluctuation, especially estrogen; heart palpitations and dizziness can accompany this symptom. Hormone-infused drugs are used to treat hot flashes, which is preferred mostly.
According to John Hopkin's Medicine, 2023, About 75% of all women have these sudden, brief, periodic increases in their body temperature. Usually, hot flashes start before a woman's last period. For 80% of women, hot flashes occur for two years or less. The treatment includes hormonal therapy, antidepressants, etc. However, estrogen therapy is the most effective treatment for relieving menopausal hot flashes.
Market Dynamics: Drivers & Restraints
Increasing menopausal women
Menopause is one of the most common conditions every woman has to go through once in life. The symptoms vary in individuals, such as hot flashes, night sweats, pain during sexual intercourse, mood swings, etc. It occurs at 50-55 in most women: the U.S. census data more than 15 million women ages 45 to 60 in the workplace. An increase in number of menopausal women worldwide is observed according to the data provided.
Menopause occurs at a median age of 51.3 years in the United States. National Institute of Health, in 2023, stated that nearly 80% of women worldwide suffer from vasomotor symptoms (VMS) that can range in severity and affect quality of life and overall health.
According to Mayo Clinic, 2022, By 2030, the world population of menopausal and postmenopausal women is projected to increase to 1.2 billion, with 47 million new entrants each year.
Furthermore, increase in expenditure of women in menopause care, increase in awareness among women, rising advancements in drug discoveries are few factors that are expected to drive the market in the forthcoming period.
Side effects of Hormonal drugs
Side effects of hormone therapy include an increased risk of endometrial cancer with long-term use. Increased risk of blood clots and stroke are observed. If the hormone therapy was started at early stages due to early menopause, there is an increased chance of dementia in women. Gallstones and gallstone problems are also common if the medication is continued for a long time.
Segment Analysis
The global menopausal hot flashes are segmented based on treatment, route of administration, distribution channel and region.
The Hormone therapy segment accounted for approximately 43.1% of the market share
Hormone therapy is expected to hold the largest share of the market. For instance, the imbalance of hormones like estrogen is the main reason for menopausal symptoms. A decrease in the level of hormones shows extreme symptoms (hot flashes, night sweats). A few healthcare startups launched hormonal supplements to combat the hot flashes in most women.
For instance, in August 2023, Rebalance Health, a startup, launched lozenges to help rebalance hormones in menopausal women who experience symptoms like hot flashes, night sweats, etc.
Furthermore, in May 2022, Hologram Sciences launched Phenology, a beauty and wellness brand with curated nutritional supplements to lower the symptoms of menopause, such as hot flashes, night sweats, mood swings, etc.
In April 2023, pH-D Feminine Health launched a new line of oral supplements to support women's menopausal health.
Geographical Analysis
North America accounted for approximately 40.2% of the market share in 2022
North America is expected to hold the largest market share due to the presence of women who experience menopausal symptoms increasing actively in the US. For instance, according to Cuyuna Regional Medical Organisation, in 2022, sixty-four million US women are 50 and older who are at menopausal age.
The cost of menopausal care is also increasing in the US because more working women are present in the US who are older than 45. For instance, according to The New York Times, 2023, Menopause costs American women an estimated $1.8 billion in lost working time per year.
According to the North American Menopause Society, 2023 By 2025, the number of postmenopausal women is expected to rise to 1.1 billion worldwide.
COVID-19 Impact Analysis
COVID-19 impact is moderate or less on the menopausal hot flashes market. Due to the rise in COVID-19 cases, there was a shift in the focus on developing drugs and vaccines to treat covid 19. The supply chain has been disrupted due to the implementation of lockdowns; this has the most impact on this market. As it is only managed and cannot be treated, home remedies were also considered as people feared visiting hospitals because of the infection spread.
Competitive Landscape
The major global players in the menopausal hot flashes market include Pfizer Inc., AbbVie Inc., Bayer, Amneal Pharmaceuticals LLC, Serum Institute of India Pvt. Ltd., Cipla Limited, Camber Pharmaceuticals, Inc., Merck KGaA, Algen Healthcare Ltd, Biosynth among others.
Key Developments
• In May 2023, Veozah (fezolinetant) developed by Astellas Pharma US, Inc. received US Food and Drug Administration approval for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.
• In October 2023, Elda Health launched a curated product portfolio to expand its horizons. It is based in India and hence aims to empower Indian women who are suffering from menopause.
Why Purchase the Report?
• To visualize the global menopausal hot flashes market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global menopausal hot flashes market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing menopausal women
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of hormonal drugs
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Menopausal women stats
5.5. Regional Analysis
5.6. Regulatory Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Hormone Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Estrogen
7.2.2.1.1. Premarin
7.2.2.1.2. Vivelle-Dot
7.2.2.1.3. Others
7.2.2.2. Progesterone
7.2.2.2.1. Prometrium
7.2.2.2.2. Others
7.2.2.3. Combination
7.2.2.3.1. Prempro
7.2.2.3.2. Duavee
7.3. Antidepressants
7.3.1. Paroxetine
7.3.2. Venlafaxine
7.4. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Injectables
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AbbVie Inc.
12.3. Bayer
12.4. Amneal Pharmaceuticals LLC
12.5. Serum Institute of India Pvt. Ltd.
12.6. Cipla Limited
12.7. Camber Pharmaceuticals, Inc.
12.8. Merck KGaA
12.9. Algen Healthcare Ltd
12.10. Biosynth
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, AbbVie Inc., Bayer, Amneal Pharmaceuticals LLC, Serum Institute of India Pvt. Ltd., Cipla Limited, Camber Pharmaceuticals, Inc., Merck KGaA, Algen Healthcare Ltd, Biosynth

표 목록 (Tables)

List of Tables

Table 1 Global Menopausal Hot Flashes Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Menopausal Hot Flashes Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Menopausal Hot Flashes Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Menopausal Hot Flashes Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Menopausal Hot Flashes Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 7 Global Menopausal Hot Flashes Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Menopausal Hot Flashes Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Menopausal Hot Flashes Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Menopausal Hot Flashes Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 14 North America Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Menopausal Hot Flashes Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 18 South America Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Menopausal Hot Flashes Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 22 Europe Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Menopausal Hot Flashes Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Menopausal Hot Flashes Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Menopausal Hot Flashes Market Value, By Treatment, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Menopausal Hot Flashes Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Menopausal Hot Flashes Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Pfizer Inc.: Overview

Table 33 Pfizer Inc.: Product Portfolio

Table 34 Pfizer Inc.: Key Developments

Table 35 AbbVie Inc.: Overview

Table 36 AbbVie Inc.: Product Portfolio

Table 37 AbbVie Inc.: Key Developments

Table 38 Bayer: Overview

Table 39 Bayer: Product Portfolio

Table 40 Bayer: Key Developments

Table 41 Amneal Pharmaceuticals LLC: Overview

Table 42 Amneal Pharmaceuticals LLC: Product Portfolio

Table 43 Amneal Pharmaceuticals LLC: Key Developments

Table 44 Serum Institute of India Pvt. Ltd.: Overview

Table 45 Serum Institute of India Pvt. Ltd.: Product Portfolio

Table 46 Serum Institute of India Pvt. Ltd.: Key Developments

Table 47 Cipla Limited: Overview

Table 48 Cipla Limited: Product Portfolio

Table 49 Cipla Limited: Key Developments

Table 50 Camber Pharmaceuticals, Inc.: Overview

Table 51 Camber Pharmaceuticals, Inc.: Product Portfolio

Table 52 Camber Pharmaceuticals, Inc.: Key Developments

Table 53 Merck KGaA: Overview

Table 54 Merck KGaA: Product Portfolio

Table 55 Merck KGaA: Key Developments

Table 56 Algen Healthcare Ltd: Overview

Table 57 Algen Healthcare Ltd: Product Portfolio

Table 58 Algen Healthcare Ltd: Key Developments

Table 59 Biosynth: Overview

Table 60 Biosynth: Product Portfolio

Table 61 Biosynth: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 2 Global Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 3 Global Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 5 Global Menopausal Hot Flashes Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Menopausal Hot Flashes Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 7 Hormone Therapy Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 8 Antidepressants Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 9 Others Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 10 Global Menopausal Hot Flashes Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 11 Oral Route of Administration in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 12 Injectables Route of Administration in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 13 Others Route of Administration in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 14 Global Menopausal Hot Flashes Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 15 Hospital Pharmacies in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 16 Retail Pharmacies in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 17 Online Pharmacies in Global Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 18 Global Menopausal Hot Flashes Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 19 North America Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 20 Asia-Pacific Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 22 South America Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 23 Middle East and Africa Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 24 North America Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 25 North America Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 26 North America Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 27 North America Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 28 North America Menopausal Hot Flashes Market Share, By Country, 2022 & 2031 (%)

Figure 29 South America Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 30 South America Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 31 South America Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 32 South America Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 33 South America Menopausal Hot Flashes Market Share, By Country, 2022 & 2031 (%)

Figure 34 Europe Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 36 Europe Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 37 Europe Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 38 Europe Menopausal Hot Flashes Market Share, By Country, 2022 & 2031 (%)

Figure 39 Asia-Pacific Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 41 Asia-Pacific Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 42 Asia-Pacific Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 43 Asia-Pacific Menopausal Hot Flashes Market Share, By Country, 2022 & 2031 (%)

Figure 44 Middle East & Africa Menopausal Hot Flashes Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East & Africa Menopausal Hot Flashes Market Share, By Treatment, 2022 & 2031 (%)

Figure 46 Middle East & Africa Menopausal Hot Flashes Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 47 Middle East & Africa Menopausal Hot Flashes Market Share, By End-User, 2022 & 2031 (%)

Figure 48 Pfizer Inc.: Financials

Figure 49 AbbVie Inc.: Financials

Figure 50 Bayer: Financials

Figure 51 Amneal Pharmaceuticals LLC: Financials

Figure 52 Serum Institute of India Pvt. Ltd.: Financials

Figure 53 Cipla Limited: Financials

Figure 54 Camber Pharmaceuticals, Inc.: Financials

Figure 55 Merck KGaA: Financials

Figure 56 Algen Healthcare Ltd: Financials

Figure 57 Biosynth: Financials

세계 폐경기 안면홍조 시장 – 2023-2030

Global Menopausal Hot Flashes Market - 2023-2030